QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Quantify published 8 papers based on cross-Nordic RWE studies in 2022! ?
A “cross-Nordic RWE study” includes an analysis of data from multiple Nordic countries. In 2022, Quantify published 8 papers, based on EMPRISE, BISCUITS, NORDSTAR and the ATTR-CM study, providing important evidence on Nordic-wide comparative effectiveness, treatment patterns and unmet needs, in various disease areas. In contrast to single country studies, cross-Nordic research provides better generalizability and can identify important Nordic differences in routine clinical care, in addition to increasing […]
Happy Holidays!
From the entire Quantify team to all of our clients, collaborators and friends – Happy Holidays and Happy New Year! We hope that 2023 brings happiness and success to you all. #HappyHolidays #NewYear #2023
Neha Singh joins Quantify as Manager, ERS!
Last week we excitedly welcomed our newest team member Dr Neha Singh as Manager within our Evidence review & synthesis unit!
Neha is enthusiastic, passionate, and has a deep interest in the subject of research which she owes to her PhD degree in Biotechnology. She has a research experience of more than 6 years and has close to 8 years of corporate experience in the field of pharmacovigilance. Her expertise […]
Study published in Acta Oncologica journal
A description of the use of ALK-TKI treatment for patients with ALK positive advanced non-small cell lung cancer, co-authored by Quantify’s Rosa Lauppe and Mathias Lilja, has been published in the Acta Oncologica journal.
Using Swedish national registry data, this study provides a unique overview of all patients treated with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors (ALK-TKI) therapies in Sweden and offers […]